Revvity, Inc. is a global provider of health science solutions, offering a comprehensive suite of technologies and services for research, diagnostics, and drug discovery, operating within the Healthcare sector's Diagnostics & Research industry. The company, formerly known as PerkinElmer, focuses on instruments, reagents, and software that facilitate genetic testing, disease screening, and genomic workflows for pharmaceutical companies, research institutions, and healthcare providers. In its most recent reported quarters, Revvity demonstrated a mixed performance. For Q4 2025, the company reported actual EPS of $1.70, exceeding the estimate of $1.58, and revenue of $772.06 million, slightly below the estimate of $776.64 million. This followed Q3 2025, where actual EPS was $1.18, matching the estimate of $1.14, with revenue at $698.95 million. Prior to this, Q2 2025 saw actual EPS of $1.18 against an estimate of $1.14, and Q1 2025 reported actual EPS of $1.01 versus an estimate of $0.95. The company has shown a pattern of beating EPS estimates in the last four reported quarters, though revenue figures have been less consistent, with a miss in Q4 2025. Looking at the historical trajectory, Revvity has generally shown year-over-year revenue growth, with EPS performance often meeting or exceeding analyst expectations. The company has a streak of beating EPS estimates in the last four quarters for which actual results are available (Q1 2025, Q2 2025, Q3 2025, Q4 2025), indicating a degree of predictability in its earnings generation relative to analyst consensus. Recent news highlights Revvity's strategic focus on innovation, including the launch of its Signals BioDesign offering, a cloud-native solution aimed at streamlining biologics research workflows for R&D teams in the biotech and pharmaceutical sectors. This platform integrates design and execution for molecular cloning, potentially accelerating drug discovery pipelines. Additionally, Evercore ISI maintained an 'Outperform' rating on the stock while adjusting its price target to $108 from $118. Investors will be watching for the company's Q1 2026 earnings report, focusing on the adoption and impact of new offerings like Signals BioDesign and how the company navigates its revised valuation targets. Key will be the continued ability to meet or exceed EPS estimates and the performance of its revenue streams in the upcoming reporting periods.
